Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Currently, the first line treatment for acromegaly is surgery, in order to remove the adenoma
causing overproduction of growth hormone which leads to acromegaly. Octreotide LAR is
approved for treatment of acromegaly after surgery if the disease is not controlled. This
study was aimed to test the safety and efficacy of octreotide LAR in acromegalic patients who
did not have any previous treatment for acromegaly.